Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 

Abstract/Editors' Note | Full Text | PDF

FIGURES/TABLES SUMMARY PAGE

PowerPoint slides are available for most Figures at Annals.org

Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency


View this table:

[in a new window]
 
Table 1. Selected Placebo-Controlled Trials in Patients with Heart Failure: Renal Function of Participants and Medication Efficacy

 

View this table:

[in a new window]
 
Table 2. Incidence of Worsened Renal Function with Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Patients with Heart Failure

 


View larger version (26K):

[in a new window]
 
Figure. Treatment algorithm for patients with systolic heart failure, based on renal function. Renal function should be categorized by estimated glomerular filtration rate (GFR), which can be calculated from the serum creatinine level. Evidence supporting a beneficial effect on clinical outcomes from each medication within subgroups of renal function is evaluated as definite, possible, or unknown by the author. These definitions are based on the range of renal function represented within the clinical trials and the reporting of results specific to patients with renal insufficiency. ACE = angiotensin-converting enzyme; ARB = angiotensin-receptor blocker. *Using Cockcroft–Gault equation (6) or Modification of Diet in Renal Disease formula (7). {dagger}Careful monitoring of renal function and electrolytes. {ddagger}Possibly harmful because of hyperkalemia risk. §Consider withholding therapy during states of volume depletion because of hyperkalemia risk. ||Shown to help reduce hospitalization but not mortality.

 





 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2003 by the American College of Physicians.